We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesKalvista Pharmaceuticals Inc

Kalvista Pharmaceuticals Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None USD 0.00(0%)
Last update at 2026-07-16T21:45:08.354244Z
Market Cap
471.03M

Momentum Score

…

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
7.21
Low
16.88
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
3.82M
Revenue Per Share
0.21
Gross Profit TTM
-80.28M
Debt / Equity
0.05
ROE
-79.33%
Net Debt
-48.01M
ROCE
-65.93%
Diluted EPS TTM
-3.12

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-04-30 2022-04-30 2021-04-30 2020-04-30 2019-04-30
Type yearly yearly yearly yearly yearly
Date 2023-04-30 2022-04-30 2021-04-30 2020-04-30 2019-04-30
Income before tax -92.91M -82.34M -46.24M -29.24M -20.69M
Net income -74.85M -68.51M -44.49M -29.12M -20.82M
Selling general administrative 30.59M 26.45M 16.64M 13.03M 10.93M
Gross profit - - 12.69M 12.69M 16.13M
Reconciled depreciation 0.72M 0.56M 0.54M 0.51M 0.38M
Ebit -110.87M -96.61M -57.92M -40.53M -29.87M
Ebitda -110.24M -94.51M -58.23M -39.65M -29.49M
Depreciation and amortization 0.63M 2.10M -0.31M 0.88M 0.38M
Non operating income net other 17.96M 14.27M 11.68M 11.29M 9.13M
Operating income -110.87M -96.61M -57.92M -40.53M -29.82M
Other operating expenses 110.87M 96.61M 57.92M 53.22M 45.95M
Interest expense -17.96M 1.09M 0.90M 10.93M 9.18M
Tax provision 0.00M 0.00M 0.00M -0.12M 0.12M
Interest income 2.23M 1.09M 0.90M 1.83M 1.40M
Net interest income 2.23M 1.09M 0.90M 1.83M 1.40M
Income tax expense -18.05M -13.83M -1.75M -0.12M 0.12M
Total revenue 0.00M 0.00M 12.69M 12.69M 16.13M
Total operating expenses 110.87M 96.61M 57.92M 53.22M 45.95M
Cost of revenue - - - - 35.02M
Total other income expense net 17.96M 14.27M 11.68M 11.29M 7.73M
Net income from continuing ops -92.91M -82.34M -46.24M -29.12M -20.82M
Net income applicable to common shares -92.91M -82.34M -46.24M -29.12M -20.82M
Breakdown 2023-04-30 2022-04-30 2021-04-30 2020-04-30 2019-04-30
Type yearly yearly yearly yearly yearly
Date 2023-04-30 2022-04-30 2021-04-30 2020-04-30 2019-04-30
Total assets 183.20M 203.88M 272.01M 92.53M 118.13M
Other current assets 6.38M 10.64M 4.92M 4.46M 3.42M
Total liab 22.18M 18.79M 14.82M 8.78M 21.39M
Total stockholder equity 161.03M 185.09M 257.19M 83.75M 96.74M
Other current liab 9.13M 6.96M 6.93M 5.46M 5.59M
Common stock 0.03M 0.03M 0.02M 0.02M 0.02M
Capital stock 0.03M 0.03M 0.02M 0.02M 0.02M
Retained earnings -343.08M -250.18M -167.84M -121.59M -92.48M
Other liab - - - - 3.34M
Other assets - 0.19M 0.20M 0.18M 0.17M
Cash 56.24M 30.73M 50.59M 15.79M 32.01M
Total current liabilities 15.03M 11.58M 9.77M 7.72M 18.05M
Current deferred revenue - - - - 9.54M
Net debt -48.01M -22.54M -44.68M -14.14M -31.95M
Short term debt 1.09M 0.98M 0.86M 0.59M 0.05M
Short long term debt total 8.23M 8.19M 5.91M 1.65M 0.05M
Other stockholder equity 507.13M 439.10M 426.44M 207.21M 191.12M
Property plant equipment 2.95M 2.18M 1.79M 2.04M 2.41M
Total current assets 172.33M 193.65M 264.26M 88.70M 115.55M
Net tangible assets 161.03M 185.09M 257.19M 83.75M 96.74M
Short term investments 93.14M 135.47M 198.34M 51.92M 68.81M
Net receivables 16.57M 14.10M 10.42M 16.53M 11.31M
Inventory - 2.71M - - -
Accounts payable 4.82M 3.64M 1.98M 1.68M 2.86M
Accumulated other comprehensive income -3.06M -3.86M -1.43M -1.88M -1.93M
Common stock total equity 0.03M 0.03M 0.02M 0.02M 0.02M
Retained earnings total equity -343.08M -250.18M -167.84M -121.59M -92.48M
Non currrent assets other 0.11M 0.19M 0.20M 0.18M 0.17M
Non current assets total 10.88M 10.23M 7.75M 3.83M 2.59M
Capital lease obligations 8.23M 8.19M 5.91M 1.65M 0.05M
Breakdown 2023-04-30 2022-04-30 2021-04-30 2020-04-30 2019-04-30
Type yearly yearly yearly yearly yearly
Date 2023-04-30 2022-04-30 2021-04-30 2020-04-30 2019-04-30
Investments 42.61M 58.79M -147.57M 16.97M -68.34M
Change to liabilities 3.04M 2.16M 1.13M -1.05M 4.20M
Total cashflows from investing activities 41.41M 57.86M -147.65M 16.75M -69.42M
Net borrowings - - - -0.05M -0.21M
Total cash from financing activities 58.12M 1.58M 212.12M 11.58M 87.94M
Change to operating activities - -14.01M 8.20M -6.95M -4.20M
Net income -92.91M -82.34M -46.24M -29.12M -20.82M
Change in cash 25.51M -19.86M 34.80M -16.22M -19.05M
Begin period cash flow 30.73M 50.59M 15.79M 32.01M 51.05M
End period cash flow 56.24M 30.73M 50.59M 15.79M 32.01M
Total cash from operating activities -75.26M -78.13M -30.17M -44.82M -36.37M
Issuance of capital stock 56.58M 0.00M 210.58M 11.42M 87.91M
Depreciation 0.72M 0.56M 0.54M 0.51M 0.38M
Other cashflows from investing activities - - - 16.97M -68.34M
Change to account receivables - - 7.46M - -
Sale purchase of stock 58.12M 1.58M 212.12M 11.64M 88.15M
Other cashflows from financing activities 1.53M 1.58M 1.53M 0.22M 0.24M
Change to netincome 8.44M 13.22M 6.39M 4.22M 2.86M
Capital expenditures 1.20M 0.93M 0.08M 0.22M 1.08M
Cash flows other operating 4.46M -14.30M 7.33M -19.57M -22.99M
Exchange rate changes - - - - -1.21M
Cash and cash equivalents changes 24.27M -18.69M 34.29M -16.48M -19.05M
Change in working capital 7.41M -12.32M 8.35M -20.64M -18.79M
Stock based compensation 9.92M 11.09M 7.12M 4.45M 2.97M
Other non cash items 0.08M 4.88M 0.11M 0.01M -0.10M
Free cash flow -76.46M -79.06M -30.25M -45.04M -37.45M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Kalvista Pharmaceuticals Inc

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.

55 Cambridge Parkway, Cambridge, MA, United States, 02142

857 999 0075

https://www.kalvista.com

118

Name Title Year Born
Mr. Thomas Andrew Crockett M.B.A. CEO & Director 1975
Mr. Benjamin L. Palleiko Chief Bus. Officer & CFO 1966
Dr. Christopher M. Yea Ph.D. Chief Devel. Officer 1964
Dr. Edward P. Feener Ph.D. Chief Scientific Officer 1960
Jarrod Aldom VP of Corp. Communications NA
Ms. Rachel M. Morten Sr. VP of Regulatory Affairs & QA NA
Dr. Michael D. Smith Pharm.D. Sr. VP of Devel. 1979
Dr. Paul K. Audhya M.B.A., M.D. Chief Medical Officer 1972
Mr. Stephen Donnelly Director of Fin. and Company Sec. NA
Mr. John B. McKune VP of Fin. 1976

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…